
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      or refractory CD123+ acute myeloid leukemia. The selections of dose levels and the number of
      subjects are based on clinical trials of similar foreign products. 36 patients will be
      enrolled. Primary objective is to explore the safety, main consideration is dose-related
      safety.
    
  